Premium
Plasma complement C3 levels in Alzheimer's disease
Author(s) -
Wang Lijun,
Liu Jun
Publication year - 2021
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.054786
Subject(s) - biomarker , dementia , complement (music) , disease , complement system , neuroimaging , medicine , alzheimer's disease , population , psychology , cognition , oncology , neuroscience , immunology , biology , antibody , complementation , gene , biochemistry , environmental health , phenotype
Background Alzheimer's disease (AD) is closely related to the loss of synapses. It has been shown that the complement system is involved in the process of synaptic elimination. We investigated whether the levels of plasma complement C3 could be a probable biomarker for the prodromal and demented AD. Method Participants included 58 cognitively normal (CN) subjects, 395 patients with late mild cognitive impairment (LMCI), and 112 AD patients enrolled in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database in the current study. Result The results showed that plasma complement C3 levels were significantly increased in AD patients compared to LMCI and CN subjects. Negative correlations between plasma complement C3 and education, MMSE were observed in all subjects. Conclusion Our findings indicate that plasma complement C3 levels may not be a valuable biomarker for the diagnosis of AD in the prodromal and dementia stages. Further studies are needed to explore the diagnostic value of plasma complement C3 based on longitudinal population.